15 0 2 0 2 B-lower_bound
kg 3 5 3 5 I-lower_bound
to 6 8 6 8 O
< 9 10 9 10 O
25 11 13 11 13 B-upper_bound
kg 14 16 14 16 I-upper_bound
( 17 18 17 18 O
Cohort 18 24 18 24 O
2 25 26 25 26 O
) 26 27 26 27 O

A 0 1 28 29 O
history 2 9 30 37 O
of 10 12 38 40 O
or 13 15 41 43 O
ongoing 16 23 44 51 O
malignancy 24 34 52 62 B-cancer
other 35 40 63 68 O
than 41 45 69 73 O
cutaneous 46 55 74 83 O
Kaposi 56 62 84 90 B-cancer
's 62 64 90 92 I-cancer
sarcoma 65 72 93 100 I-cancer
( 73 74 101 102 I-cancer
KS 74 76 102 104 I-cancer
) 76 77 104 105 I-cancer
, 77 78 105 106 O
basal 79 84 107 112 B-cancer
cell 85 89 113 117 I-cancer
carcinoma 90 99 118 127 I-cancer
, 99 100 127 128 O
or 101 103 129 131 O
resected 104 112 132 140 O
, 112 113 140 141 O
non 114 117 142 145 O
- 117 118 145 146 O
invasive 118 126 146 154 O
cutaneous 127 136 155 164 O
squamous 137 145 165 173 B-cancer
carcinoma 146 155 174 183 I-cancer

Active 0 6 184 190 O
hepatitis 7 16 191 200 B-chronic_disease
C 17 18 201 202 I-chronic_disease
virus 19 24 203 208 I-chronic_disease
( 25 26 209 210 I-chronic_disease
HCV 26 29 210 213 I-chronic_disease
) 29 30 213 214 I-chronic_disease
infection 31 40 215 224 I-chronic_disease

An 0 2 225 227 O
AIDS 3 7 228 232 B-chronic_disease
defining 8 16 233 241 O
condition 17 26 242 251 O
with 27 31 252 256 O
onset 32 37 257 262 O
within 38 44 263 269 O
30 45 47 270 272 B-upper_bound
days 48 52 273 277 I-upper_bound
prior 53 58 278 283 I-upper_bound
to 59 61 284 286 O
screening 62 71 287 296 O

An 0 2 297 299 O
ongoing 3 10 300 307 O
serious 11 18 308 315 O
infection 19 28 316 325 O
requiring 29 38 326 335 O
systemic 39 47 336 344 B-treatment
antibiotic 48 58 345 355 I-treatment
therapy 59 66 356 363 I-treatment
at 67 69 364 366 O
the 70 73 367 370 O
time 74 78 371 375 O
of 79 81 376 378 O
screening 82 91 379 388 O

Anticipated 0 11 389 400 O
requirement 12 23 401 412 O
for 24 27 413 416 O
rifamycin 28 37 417 426 B-treatment
treatment 38 47 427 436 I-treatment
while 48 53 437 442 O
participating 54 67 443 456 O
in 68 70 457 459 O
the 71 74 460 463 O
study 75 80 464 469 O

At 0 2 470 472 O
anytime 3 10 473 480 O
for 11 14 481 484 O
individuals 15 26 485 496 O
younger 27 34 497 504 O
than 35 39 505 509 O
6 40 41 510 511 B-upper_bound
months 42 48 512 518 I-upper_bound

Body 0 4 519 523 B-clinical_variable
weight 5 11 524 530 I-clinical_variable
at 12 14 531 533 O
screening 15 24 534 543 O
≥ 25 26 544 545 O
25 27 29 546 548 B-lower_bound
kg 30 32 549 551 I-lower_bound
( 33 34 552 553 O
Cohorts 34 41 553 560 O
1 42 43 561 562 O
and 44 47 563 566 O
2 48 49 567 568 O
) 49 50 568 569 O

Documented 0 10 570 580 O
negative 11 19 581 589 O
screening 20 29 590 599 O
for 30 33 600 603 O
active 34 40 604 610 O
pulmonary 41 50 611 620 B-chronic_disease
tuberculosis 51 63 621 633 I-chronic_disease
( 64 65 634 635 I-chronic_disease
TB 65 67 635 637 I-chronic_disease
) 67 68 637 638 I-chronic_disease
per 69 72 639 642 O
local 73 78 643 648 O
standard 79 87 649 657 O
of 88 90 658 660 O
care 91 95 661 665 O

Evidence 0 8 666 674 O
of 9 11 675 677 O
active 12 18 678 684 O
pulmonary 19 28 685 694 B-chronic_disease
or 29 31 695 697 O
extra 32 37 698 703 B-chronic_disease
- 37 38 703 704 I-chronic_disease
pulmonary 38 47 704 713 I-chronic_disease
tuberculosis 48 60 714 726 I-chronic_disease
disease 61 68 727 734 I-chronic_disease

HIV-1 0 5 735 740 B-chronic_disease
infected 6 14 741 749 O
treatment 15 24 750 759 B-treatment
- 24 25 759 760 O
experienced 25 36 760 771 O
, 36 37 771 772 O
virologically 38 51 773 786 O
suppressed 52 62 787 797 O
males 63 68 798 803 B-gender

Have 0 4 804 808 O
any 5 8 809 812 O
serious 9 16 813 820 O
or 17 19 821 823 O
active 20 26 824 830 O
medical 27 34 831 838 O
or 35 37 839 841 O
psychiatric 38 49 842 853 B-chronic_disease
illness 50 57 854 861 I-chronic_disease
which 58 63 862 867 O
, 63 64 867 868 O
in 65 67 869 871 O
the 68 71 872 875 O
opinion 72 79 876 883 O
of 80 82 884 886 O
the 83 86 887 890 O
investigator 87 99 891 903 O
, 99 100 903 904 O
would 101 106 905 910 O
interfere 107 116 911 920 O
with 117 121 921 925 O
treatment 122 131 926 935 B-treatment
, 131 132 935 936 O
assessment 133 143 937 947 O
, 143 144 947 948 O
or 145 147 949 951 O
compliance 148 158 952 962 O
with 159 163 963 967 O
the 164 167 968 971 O
protocol 168 176 972 980 O

Have 0 4 981 985 O
history 5 12 986 993 O
of 13 15 994 996 O
significant 16 27 997 1008 O
drug 28 32 1009 1013 B-allergy_name
sensitivity 33 44 1014 1025 I-allergy_name
or 45 47 1026 1028 O
drug 48 52 1029 1033 B-allergy_name
allergy 53 60 1034 1041 I-allergy_name

Have 0 4 1042 1046 O
previously 5 15 1047 1057 B-treatment
participated 16 28 1058 1070 I-treatment
in 29 31 1071 1073 I-treatment
an 32 34 1074 1076 I-treatment
investigational 35 50 1077 1092 I-treatment
trial 51 56 1093 1098 I-treatment
involving 57 66 1099 1108 O
administration 67 81 1109 1123 O
of 82 84 1124 1126 O
any 85 88 1127 1130 O
investigational 89 104 1131 1146 B-treatment
agent 105 110 1147 1152 I-treatment

Hepatic 0 7 1153 1160 O
transaminases 8 21 1161 1174 O
( 22 23 1175 1176 O
AST 23 26 1176 1179 B-clinical_variable
and 27 30 1180 1183 O
ALT 31 34 1184 1187 B-clinical_variable
) 34 35 1187 1188 O

Individuals 0 11 1189 1200 O
experiencing 12 24 1201 1213 O
decompensated 25 38 1214 1227 B-chronic_disease
cirrhosis 39 48 1228 1237 I-chronic_disease

Individuals 0 11 1238 1249 O
receiving 12 21 1250 1259 O
ongoing 22 29 1260 1267 O
therapy 30 37 1268 1275 B-treatment
with 38 42 1276 1280 O
any 43 46 1281 1284 O
medication 47 57 1285 1295 B-treatment
that 58 62 1296 1300 O
is 63 65 1301 1303 O
not 66 69 1304 1307 O
to 70 72 1308 1310 O
be 73 75 1311 1313 O
taken 76 81 1314 1319 O
with 82 86 1320 1324 O
COBI 87 91 1325 1329 O
or 92 94 1330 1332 O
a 95 96 1333 1334 O
component 97 106 1335 1344 O
of 107 109 1345 1347 O
the 110 113 1348 1351 O
BR 114 116 1352 1354 O

Individuals 0 11 1355 1366 O
with 12 16 1367 1371 O
CD4 17 20 1372 1375 B-clinical_variable
+ 20 21 1375 1376 I-clinical_variable
cell 22 26 1377 1381 I-clinical_variable
counts 27 33 1382 1388 I-clinical_variable
at 34 36 1389 1391 O
screening 37 46 1392 1401 O
of 47 49 1402 1404 O
less 50 54 1405 1409 O
than 55 59 1410 1414 O
200 60 63 1415 1418 B-upper_bound
cells 64 69 1419 1424 I-upper_bound
/ 69 70 1424 1425 I-upper_bound
mm^3 70 74 1425 1429 I-upper_bound

Known 0 5 1430 1435 O
hypersensitivity 6 22 1436 1452 B-allergy_name
to 23 25 1453 1455 O
the 26 29 1456 1459 O
study 30 35 1460 1465 B-allergy_name
drug 36 40 1466 1470 I-allergy_name
, 40 41 1470 1471 O
the 42 45 1472 1475 O
metabolites 46 57 1476 1487 B-allergy_name
, 57 58 1487 1488 O
or 59 61 1489 1491 O
formulation 62 73 1492 1503 B-allergy_name
excipients 74 84 1504 1514 I-allergy_name

Life 0 4 1515 1519 B-clinical_variable
expectancy 5 15 1520 1530 I-clinical_variable
of 16 18 1531 1533 O
less 19 23 1534 1538 O
than 24 28 1539 1543 O
1 29 30 1544 1545 B-upper_bound
year 31 35 1546 1550 I-upper_bound

Males 0 5 1551 1556 B-gender

Negative 0 8 1557 1565 B-pregnancy
serum 9 14 1566 1571 I-pregnancy
pregnancy 15 24 1572 1581 I-pregnancy
test 25 29 1582 1586 O

No 0 2 1587 1589 O
opportunistic 3 16 1590 1603 B-chronic_disease
infection 17 26 1604 1613 I-chronic_disease
within 27 33 1614 1620 O
30 34 36 1621 1623 B-upper_bound
days 37 41 1624 1628 I-upper_bound
of 42 44 1629 1631 O
study 45 50 1632 1637 O
entry 51 56 1638 1643 O
( 57 58 1644 1645 O
at 58 60 1645 1647 O
Day 61 64 1648 1651 O
-10 65 68 1652 1655 O
) 68 69 1655 1656 O

Participation 0 13 1657 1670 O
in 14 16 1671 1673 O
any 17 20 1674 1677 O
other 21 26 1678 1683 O
clinical 27 35 1684 1692 B-treatment
trial 36 41 1693 1698 I-treatment
, 41 42 1698 1699 O
including 43 52 1700 1709 O
observational 53 66 1710 1723 O
studies 67 74 1724 1731 O
, 74 75 1731 1732 O
without 76 83 1733 1740 O
prior 84 89 1741 1746 O
approval 90 98 1747 1755 O
from 99 103 1756 1760 O
sponsor 104 111 1761 1768 O
is 112 114 1769 1771 O
prohibited 115 125 1772 1782 O
while 126 131 1783 1788 O
participating 132 145 1789 1802 O
in 146 148 1803 1805 O
this 149 153 1806 1810 O
trial 154 159 1811 1816 O

Positive 0 8 1817 1825 O
Hepatitis 9 18 1826 1835 B-chronic_disease
B 19 20 1836 1837 I-chronic_disease
surface 21 28 1838 1845 O
antigen 29 36 1846 1853 O
or 37 39 1854 1856 O
other 40 45 1857 1862 O
evidence 46 54 1863 1871 O
of 55 57 1872 1874 O
active 58 64 1875 1881 O
hepatitis 65 74 1882 1891 B-chronic_disease
B 75 76 1892 1893 I-chronic_disease
virus 77 82 1894 1899 I-chronic_disease
( 83 84 1900 1901 I-chronic_disease
HBV 84 87 1901 1904 I-chronic_disease
) 87 88 1904 1905 I-chronic_disease
infection 89 98 1906 1915 O

Pregnant 0 8 1916 1924 B-pregnancy

Stable 0 6 1925 1931 O
antiretroviral 7 21 1932 1946 B-treatment
regimen 22 29 1947 1954 I-treatment
including 30 39 1955 1964 O
2 40 41 1965 1966 O
nucleoside 42 52 1967 1977 B-treatment
reverse 53 60 1978 1985 I-treatment
transcriptase 61 74 1986 1999 I-treatment
inhibitors 75 85 2000 2010 I-treatment

Total 0 5 2011 2016 B-clinical_variable
bilirubin 6 15 2017 2026 I-clinical_variable
≤ 16 17 2027 2028 O
1.5 18 21 2029 2032 B-upper_bound
mg 22 24 2033 2035 I-upper_bound
/ 24 25 2035 2036 I-upper_bound
dL 25 27 2036 2038 I-upper_bound

Treatment 0 9 2039 2048 O
- 9 10 2048 2049 O
experienced 10 21 2049 2060 O
pediatric 22 31 2061 2070 O
individuals 32 43 2071 2082 O
taking 44 50 2083 2089 O
DRV 51 54 2090 2093 B-treatment
/ 54 55 2093 2094 I-treatment
r 55 56 2094 2095 I-treatment
must 57 61 2096 2100 O
have 62 66 2101 2105 O
no 67 69 2106 2108 O
history 70 77 2109 2116 O
of 78 80 2117 2119 O
DRV 81 84 2120 2123 O
resistance 85 95 2124 2134 O
associated 96 106 2135 2145 O
mutations 107 116 2146 2155 O

Within 0 6 2156 2162 O
3 7 8 2163 2164 B-upper_bound
months 9 15 2165 2171 I-upper_bound
of 16 18 2172 2174 O
the 19 22 2175 2178 O
screening 23 32 2179 2188 O
visit 33 38 2189 2194 O
for 39 42 2195 2198 O
all 43 46 2199 2202 O
individuals 47 58 2203 2214 O
6 59 60 2215 2216 B-lower_bound
months 61 67 2217 2223 I-lower_bound
of 68 70 2224 2226 O
age 71 74 2227 2230 B-age
or 75 77 2231 2233 O
older 78 83 2234 2239 O

a 0 1 2240 2241 O
normal 2 8 2242 2248 O
direct 9 15 2249 2255 B-clinical_variable
bilirubin 16 25 2256 2265 I-clinical_variable

aged 0 4 2266 2270 B-age
3 5 6 2271 2272 B-lower_bound
months 7 13 2273 2279 I-lower_bound
to 14 16 2280 2282 O
< 17 18 2283 2284 O
18 19 21 2285 2287 B-upper_bound
years 22 27 2288 2293 I-upper_bound

either 0 6 2294 2300 O
ritonavir 7 16 2301 2310 B-treatment
- 16 17 2310 2311 O
boosted 17 24 2311 2318 O
atazanavir 25 35 2319 2329 B-treatment
or 36 38 2330 2332 O
ritonavir 39 48 2333 2342 O
- 48 49 2342 2343 O
boosted 49 56 2343 2350 O
darunavir 57 66 2351 2360 B-treatment
once 67 71 2361 2365 O
or 72 74 2366 2368 O
twice 75 80 2369 2374 O
daily 81 86 2375 2380 O
as 87 89 2381 2383 O
per 90 93 2384 2387 O
product 94 101 2388 2395 O
label 102 107 2396 2401 O
for 108 111 2402 2405 O
a 112 113 2406 2407 O
minimum 114 121 2408 2415 O
of 122 124 2416 2418 O
3 125 126 2419 2420 B-upper_bound
months 127 133 2421 2427 I-upper_bound
prior 134 139 2428 2433 O
to 140 142 2434 2436 O
the 143 146 2437 2440 O
screening 147 156 2441 2450 O
visit 157 162 2451 2456 O

females 0 7 2457 2464 B-gender

females 0 7 2465 2472 B-gender
of 8 10 2473 2475 O
childbearing 11 23 2476 2488 O
potential 24 33 2489 2498 O
must 34 38 2499 2503 O
agree 39 44 2504 2509 B-contraception_consent
to 45 47 2510 2512 I-contraception_consent
utilize 48 55 2513 2520 I-contraception_consent
highly 56 62 2521 2527 I-contraception_consent
effective 63 72 2528 2537 I-contraception_consent
contraception 73 86 2538 2551 I-contraception_consent
methods 87 94 2552 2559 I-contraception_consent
while 95 100 2560 2565 O
on 101 103 2566 2568 O
study 104 109 2569 2574 O
treatment 110 119 2575 2584 B-treatment
or 120 122 2585 2587 O
agree 123 128 2588 2593 O
to 129 131 2594 2596 O
abstain 132 139 2597 2604 O
from 140 144 2605 2609 O
heterosexual 145 157 2610 2622 O
intercourse 158 169 2623 2634 O
throughout 170 180 2635 2645 O
the 181 184 2646 2649 O
study 185 190 2650 2655 O
period 191 197 2656 2662 O

for 0 3 2663 2666 O
30 4 6 2667 2669 B-upper_bound
days 7 11 2670 2674 I-upper_bound
following 12 21 2675 2684 O
the 22 25 2685 2688 O
last 26 30 2689 2693 O
dose 31 35 2694 2698 O
of 36 38 2699 2701 O
study 39 44 2702 2707 O
drug 45 49 2708 2712 O

individuals 0 11 2713 2724 O
with 12 16 2725 2729 O
positive 17 25 2730 2738 O
HBV 26 29 2739 2742 B-chronic_disease
surface 30 37 2743 2750 O
antibody 38 46 2751 2759 O
and 47 50 2760 2763 O
no 51 53 2764 2766 O
evidence 54 62 2767 2775 O
of 63 65 2776 2778 O
active 66 72 2779 2785 O
HBV 73 76 2786 2789 B-chronic_disease
infection 77 86 2790 2799 I-chronic_disease
are 87 90 2800 2803 O
permitted 91 100 2804 2813 O
to 101 103 2814 2816 O
enroll 104 110 2817 2823 O

individuals 0 11 2824 2835 O
with 12 16 2836 2840 O
positive 17 25 2841 2849 O
HCV 26 29 2850 2853 B-chronic_disease
antibody 30 38 2854 2862 O
and 39 42 2863 2866 O
without 43 50 2867 2874 O
detectable 51 61 2875 2885 O
HCV 62 65 2886 2889 O
RNA 66 69 2890 2893 O
are 70 73 2894 2897 O
permitted 74 83 2898 2907 O
to 84 86 2908 2910 O
enroll 87 93 2911 2917 O

lactating 0 9 2918 2927 O
females 10 17 2928 2935 B-gender

prophylactic 0 12 2936 2948 B-treatment
isoniazid 13 22 2949 2958 I-treatment
therapy 23 30 2959 2966 I-treatment
for 31 34 2967 2970 O
latent 35 41 2971 2977 B-chronic_disease
TB 42 44 2978 2980 I-chronic_disease
is 45 47 2981 2983 O
allowed 48 55 2984 2991 O

to 0 2 2992 2994 O
be 3 5 2995 2997 O
determined 6 16 2998 3008 O
( 17 18 3009 3010 O
Cohorts 18 25 3010 3017 O
3 26 27 3018 3019 O
and 28 31 3020 3023 O
4 32 33 3024 3025 O
) 33 34 3025 3026 O
dependent 35 44 3027 3036 O
upon 45 49 3037 3041 O
age 50 53 3042 3045 B-age
cohort 54 60 3046 3052 O

within 0 6 3053 3059 O
30 7 9 3060 3062 B-upper_bound
days 10 14 3063 3067 I-upper_bound
prior 15 20 3068 3073 I-upper_bound
to 21 23 3074 3076 O
the 24 27 3077 3080 O
study 28 33 3081 3086 O
dosing 34 40 3087 3093 O

≤ 0 1 3094 3095 O
5 2 3 3096 3097 B-upper_bound
x 4 5 3098 3099 I-upper_bound
upper 6 11 3100 3105 I-upper_bound
limit 12 17 3106 3111 I-upper_bound
of 18 20 3112 3114 I-upper_bound
normal 21 27 3115 3121 I-upper_bound
( 28 29 3122 3123 I-upper_bound
ULN 29 32 3123 3126 I-upper_bound
) 32 33 3126 3127 I-upper_bound

